UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 57

Sortiert nach

Tumor necrosis factor antagonist mechanisms of action: a comprehensive review

Pharmacology & therapeutics (Oxford), 2008-02, Vol.117 (2), p.244-279

2008

Volltextzugriff (PDF)

Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial

Annals of the rheumatic diseases, 2015-06, Vol.74 (6), p.1102-1109

2015

Volltextzugriff (PDF)

External validation of a multi-biomarker-based score for predicting risk of cardiovascular disease in patients with rheumatoid arthritis

PloS one, 2024-05, Vol.19 (5), p.e0296459-e0296459

2024

Volltextzugriff (PDF)

Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: Results from an open-label extension study for patients from REVEAL

Journal of the American Academy of Dermatology, 2012-02, Vol.66 (2), p.241-251

2012

Volltextzugriff (PDF)

Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor

Clinical immunology (Orlando, Fla.), 2009-05, Vol.131 (2), p.308-316

2009

Volltextzugriff (PDF)

Derivation and internal validation of a multi-biomarker-based cardiovascular disease risk prediction score for rheumatoid arthritis patients

Arthritis research & therapy, 2020-12, Vol.22 (1), p.282-282, Article 282

2020

Volltextzugriff (PDF)

ACPA-negative RA consists of subgroups: patients with high likelihood of achieving sustained DMARD-free remission can be identified by serological markers at disease presentation

Arthritis research & therapy, 2019-05, Vol.21 (1), p.121-121, Article 121

2019

Volltextzugriff (PDF)

Validation of the adjusted multi-biomarker disease activity score as a prognostic test for radiographic progression in rheumatoid arthritis: a combined analysis of multiple studies

Arthritis research & therapy, 2021-01, Vol.23 (1), p.1-1, Article 1

2021

Volltextzugriff (PDF)

Multi-biomarker disease activity score as a predictor of disease relapse in patients with rheumatoid arthritis stopping TNF inhibitor treatment

PloS one, 2018-05, Vol.13 (5), p.e0192425-e0192425

2018

Volltextzugriff (PDF)

Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy

Journal of rheumatology, 2007-05, Vol.34 (5), p.1040

2007

Volltextzugriff (PDF)

Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis

Journal of rheumatology, 2009-07, Vol.36 (7), p.1429

2009

Volltextzugriff (PDF)

A multibiomarker disease activity score for rheumatoid arthritis predicts radiographic joint damage in the BeSt study

Journal of rheumatology, 2014-11, Vol.41 (11), p.2114

2014

Volltextzugriff (PDF)

The multi-biomarker disease activity score tracks response to rituximab treatment in rheumatoid arthritis patients: a post hoc analysis of three cohort studies

Arthritis research & therapy, 2018-11, Vol.20 (1), p.256-256, Article 256

2018

Volltextzugriff (PDF)

Reanalysis of the Multi‐Biomarker Disease Activity Score for Assessing Disease Activity in the Abatacept Versus Adalimumab Comparison in Biologic‐Naive Rheumatoid Arthritis Subjects with Background Methotrexate Study: Comment on the Article by Fleischmann et al

Arthritis & rheumatology (Hoboken, N.J.), 2017-04, Vol.69 (4), p.863-865

2017

Volltextzugriff (PDF)

Multibiomarker disease activity score and C-reactive protein in a cross-sectional observational study of patients with rheumatoid arthritis with and without concomitant fibromyalgia

Rheumatology (Oxford, England), 2016-04, Vol.55 (4), p.640-648

2016

Volltextzugriff (PDF)

Predicting risk for radiographic damage in rheumatoid arthritis: comparative analysis of the multi-biomarker disease activity score and conventional measures of disease activity in multiple studies

Current medical research and opinion, 2019-09, Vol.35 (9), p.1483-1493

2019

Volltextzugriff (PDF)

Adjustment of the multi-biomarker disease activity score to account for age, sex and adiposity in patients with rheumatoid arthritis

Rheumatology (Oxford, England), 2019-05, Vol.58 (5), p.874-883

2019

Volltextzugriff (PDF)

A multi-biomarker score measuring disease activity in rheumatoid arthritis patients tapering adalimumab or etanercept: predictive value for clinical and radiographic outcomes

Rheumatology (Oxford, England), 2017-06, Vol.56 (6), p.973-980

2017

Volltextzugriff (PDF)

Relationship of multi-biomarker disease activity score and other risk factors with radiographic progression in an observational study of patients with rheumatoid arthritis

Rheumatology (Oxford, England), 2016-02, Vol.55 (2), p.357-366

2016

Volltextzugriff (PDF)

Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT

Arthritis research & therapy, 2010-01, Vol.12 (3), p.R113-R113

2010

Volltextzugriff (PDF)

Interpreting the multi-biomarker disease activity score in the context of tocilizumab treatment for patients with rheumatoid arthritis

Rheumatology international, 2016-02, Vol.36 (2), p.295-300

2016

Volltextzugriff (PDF)

Impact of a multi-biomarker disease activity test on rheumatoid arthritis treatment decisions and therapy use

Current medical research and opinion, 2013-01, Vol.29 (1), p.85-92

2013

Volltextzugriff (PDF)

Brief Report: Enhancement of Patient Recruitment in Rheumatoid Arthritis Clinical Trials Using a Multi‐Biomarker Disease Activity Score as an Inclusion Criterion

Arthritis & rheumatology (Hoboken, N.J.), 2015-11, Vol.67 (11), p.2855-2860

2015

Volltextzugriff (PDF)

Does the multi-biomarker disease activity score have diagnostic value in early rheumatoid arthritis and unclassified arthritis?

Annals of the rheumatic diseases, 2015-11, Vol.74 (11), p.2097-2099

2015

Volltextzugriff (PDF)

Association of a multibiomarker disease activity score at multiple time-points with radiographic progression in rheumatoid arthritis: results from the SWEFOT trial

Rheumatic & musculoskeletal diseases open, 2016-01, Vol.2 (1), p.e000197-e000197

2016

Volltextzugriff (PDF)

1 – 25 von 57

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(50)
Mit Volltextzugriff
(41)

Publikationsform

Artikel
(53)
Bücher
(4)

Sprache

Englisch
(54)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

Science & Technology
(42)
Humans
(41)
Life Sciences & Biomedicine
(39)
Female
(25)
Male
(24)
Rheumatology
(23)
Rheumatoid Arthritis
(21)
Middle Aged
(19)
Adult
(16)
Biological And Medical Sciences
(15)
Aged
(12)
Antirheumatic Agents - Therapeutic Use
(12)
Arthritis, Rheumatoid - Drug Therapy
(10)
Immunoglobulin Variable Region - Genetics
(10)
Severity Of Illness Index
(10)
Biomarkers
(9)
Immunoglobulin Heavy Chains - Genetics
(9)
Immunology
(9)
Medical Sciences
(9)
Treatment Outcome
(9)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Tumor necrosis factor antagonist mechanisms of action: a comprehensive review

Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial

External validation of a multi-biomarker-based score for predicting risk of cardiovascular disease in patients with rheumatoid arthritis

Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: Results from an open-label extension study for patients from REVEAL

Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor

Derivation and internal validation of a multi-biomarker-based cardiovascular disease risk prediction score for rheumatoid arthritis patients

ACPA-negative RA consists of subgroups: patients with high likelihood of achieving sustained DMARD-free remission can be identified by serological markers at disease presentation

Validation of the adjusted multi-biomarker disease activity score as a prognostic test for radiographic progression in rheumatoid arthritis: a combined analysis of multiple studies

Multi-biomarker disease activity score as a predictor of disease relapse in patients with rheumatoid arthritis stopping TNF inhibitor treatment

Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy

Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis

A multibiomarker disease activity score for rheumatoid arthritis predicts radiographic joint damage in the BeSt study

The multi-biomarker disease activity score tracks response to rituximab treatment in rheumatoid arthritis patients: a post hoc analysis of three cohort studies

Reanalysis of the Multi‐Biomarker Disease Activity Score for Assessing Disease Activity in the Abatacept Versus Adalimumab Comparison in Biologic‐Naive Rheumatoid Arthritis Subjects with Background Methotrexate Study: Comment on the Article by Fleischmann et al

Multibiomarker disease activity score and C-reactive protein in a cross-sectional observational study of patients with rheumatoid arthritis with and without concomitant fibromyalgia

Predicting risk for radiographic damage in rheumatoid arthritis: comparative analysis of the multi-biomarker disease activity score and conventional measures of disease activity in multiple studies

Adjustment of the multi-biomarker disease activity score to account for age, sex and adiposity in patients with rheumatoid arthritis

A multi-biomarker score measuring disease activity in rheumatoid arthritis patients tapering adalimumab or etanercept: predictive value for clinical and radiographic outcomes

Relationship of multi-biomarker disease activity score and other risk factors with radiographic progression in an observational study of patients with rheumatoid arthritis

Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT

Interpreting the multi-biomarker disease activity score in the context of tocilizumab treatment for patients with rheumatoid arthritis

Impact of a multi-biomarker disease activity test on rheumatoid arthritis treatment decisions and therapy use

Brief Report: Enhancement of Patient Recruitment in Rheumatoid Arthritis Clinical Trials Using a Multi‐Biomarker Disease Activity Score as an Inclusion Criterion

Does the multi-biomarker disease activity score have diagnostic value in early rheumatoid arthritis and unclassified arthritis?

Association of a multibiomarker disease activity score at multiple time-points with radiographic progression in rheumatoid arthritis: results from the SWEFOT trial

Suchergebnisse filtern